- First-line gemcitabine+eribulin is well tolerated and shows an overall response rate (ORR) of 50% in cisplatin-ineligible patients with metastatic urothelial carcinoma.
Why this matters
- The response rate was higher than standard-of-care gemcitabine-carboplatin and immunotherapy.
- Overall response, OS, and PFS with gemcitabine+eribulin were higher than those previously reported with eribulin monotherapy.
- Phase 2 study of 24 cisplatin-ineligible patients (performance status, 0-2; median age, 73 years) with treatment-naive advanced/recurrent metastatic urothelial bladder cancer not amenable to surgery received gemcitabine+eribulin.
- Funding: Pfizer; MSD.
- Median number of cycles, 4.
- Median follow-up, 16.8 months.
- Confirmed ORR was 50% (95% CI, 29%-71%).
- Median duration of response was 3.1 months.
- Median OS was 11.9 (95% CI, 5.6-20.4) months; median PFS was 5.3 (95% CI, 4.5-6.7) months.
- Common treatment-related toxicities included fatigue (83%), neutropenia (79%), anemia (63%), alopecia (50%), elevated aspartate aminotransferase (50%).
- 13% of patients experienced febrile neutropenia.
- 2 deaths were reported.
- Single-group, small study.